CASI Pharmaceuticals

CASI Pharmaceuticals focuses on building a pipeline through mutually beneficial business development transactions. The Company's strategy leverages its resources and expertise in China to develop and commercialize innovative products in China and other markets.
Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
1991
Size (employees)
26 (est)+30%
CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, US

Key People/Management at CASI Pharmaceuticals

Sara Capitelli

Sara Capitelli

Vice President, Finance and Principal Accounting Officer

CASI Pharmaceuticals Office Locations

CASI Pharmaceuticals has offices in Rockville and Beijing
Rockville, US (HQ)
300 9620 Medical Center Dr
Beijing, CN
CASI (Beijing) Pharmaceuticals, Inc. FullLink Plaza Suite B1214, B1215 18 Chaoyangmenwai Street, Chaoyang
Show all (2)

CASI Pharmaceuticals Financials and Metrics

CASI Pharmaceuticals Financials

CASI Pharmaceuticals's revenue was reported to be $47.7 k in FY, 2015
USD

Net income (Q3, 2017)

(1.6 m)

Market capitalization (16-Feb-2018)

231.2 m

Cash (30-Sep-2017)

21.6 m
CASI Pharmaceuticals's current market capitalization is $231.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.7 k47.7 k

Revenue growth, %

101%

Cost of goods sold

7.5 k6.3 k

Gross profit

16.3 k41.4 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cost of goods sold

6.3 k2.7 k

R&D expense

793.8 k560 k724.5 k697 k865 k1.2 m942.3 k1 m1.4 m1 m1 m1.7 m971 k

General and administrative expense

648.7 k891.4 k891.9 k1.2 m924.8 k857.6 k673.9 k765.1 k1.9 m676.9 k644.2 k691.4 k625.9 k

Operating expense total

1.4 m1.5 m1.6 m1.8 m1.8 m2.1 m1.6 m1.8 m3.3 m1.7 m1.7 m2.4 m1.6 m
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

6.3 m4.9 m1.1 m8 m15.1 m10.7 m5.1 m27.1 m

Current Assets

15.4 m11 m5.6 m27.4 m

PP&E

78.1 k261.8 k218.8 k229.6 k

Total Assets

15.5 m11.3 m5.8 m27.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

15.9 m14.2 m13.1 m11.8 m9.5 m8 m6.4 m13.9 m18.5 m24.1 m25.5 m23.4 m21.6 m

Current Assets

16.2 m14.5 m13.2 m12.2 m9.9 m8.3 m6.8 m14.3 m18.8 m24.5 m25.9 m23.6 m22.1 m

PP&E

56.6 k113.7 k240.4 k230.6 k246.3 k245.3 k234.7 k222.8 k168.7 k184.1 k244.6 k448.5 k566 k

Total Assets

16.3 m14.6 m13.5 m12.4 m10.2 m8.6 m7.1 m14.5 m19 m24.8 m26.2 m24.1 m22.7 m
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (26.2 m)(7.2 m)(9.5 m)

    Depreciation and Amortization

    48.2 k68.4 k66.5 k

    Accounts Receivable

    (23.7 k)23.7 k

    Accounts Payable

    352.2 k129.5 k180.5 k
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    (4.4 m)(1.5 m)(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)

    Depreciation and Amortization

    12.9 k6.5 k19.2 k32.7 k

    Accounts Receivable

    669.3 k

    Accounts Payable

    (152.6 k)189.3 k171.1 k197.8 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m
      Y, 2017

      Financial Leverage

      1.5 x
      Show all financial metrics

      CASI Pharmaceuticals Market Value History

      CASI Pharmaceuticals's Web-traffic and Trends

      CASI Pharmaceuticals Company Life and Culture

      You may also be interested in